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Bacterial infections of the lungs of cystic fibrosis (CF) patients cause major complications in the treatment
of this common genetic disease. Burkholderia cenocepacia infection is particularly problematic since this
organism has high levels of antibiotic resistance, making it difficult to eradicate; the resulting chronic
infections are associated with severe declines in lung function and increased mortality rates. B. cenocepacia
strain J2315 was isolated from a CF patient and is a member of the epidemic ET12 lineage that originated in
Canada or the United Kingdom and spread to Europe. The 8.06-Mb genome of this highly transmissible
pathogen comprises three circular chromosomes and a plasmid and encodes a broad array of functions typical
of this metabolically versatile genus, as well as numerous virulence and drug resistance functions. Although B.
cenocepacia strains can be isolated from soil and can be pathogenic to both plants and man, J2315 is
representative of a lineage of B. cenocepacia rarely isolated from the environment and which spreads between
CF patients. Comparative analysis revealed that ca. 21% of the genome is unique in comparison to other strains
of B. cenocepacia, highlighting the genomic plasticity of this species. Pseudogenes in virulence determinants
suggest that the pathogenic response of J2315 may have been recently selected to promote persistence in the
CF lung. The J2315 genome contains evidence that its unique and highly adapted genetic content has played
a significant role in its success as an epidemic CF pathogen.
Burkholderia cenocepacia is the most clinically important
member of B. cepacia complex (BCC) group of opportunistic
pathogens to cause lung infections in cystic fibrosis (CF) pa-
tients (83, 140). The BCC (originally described as Pseudomo-
nas cepacia) emerged as significant CF pathogens in the early
1980s when a minority of infected patients exhibited rapid
clinical deterioration due to necrotizing pneumonia and sepsis,
resulting in early death (54). This fatal decline in clinical con-
dition became known as “cepacia syndrome” and has not been
observed with any other CF pathogen. The key determinants
associated with this syndrome are not clear; clonal isolates can
be isolated from patients with or without cepacia syndrome,
suggesting that both bacterial and host factors play important
roles in determining clinical prognosis (44, 57). During the
1990s a highly transmissible epidemic B. cenocepacia lineage
emerged that was readily spread between individuals with CF
(44); multilocus enzyme electrophoresis designated it as elec-
trophoretic type 12 (ET12) (56). Subsequent studies showed
that this B. cenocepacia strain was widespread across Canadian
(80, 126), United Kingdom (44), and European (140) CF com-
munities and was suggested to have spread through patient-to-
patient contacts, including those at CF summer camps (44).
At least 17 species comprise the BCC (79, 141, 142), a
diverse collection of genetically distinct but phenotypically sim-
ilar strains that includes bioremediation and biocontrol strains,
as well as plant, animal, and human pathogens (83). Although
strains from each of the BCC species have been isolated from
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CF infection (83), epidemics are largely attributed to B. ceno-
cepacia (25, 27) and Burkholderia multivorans (120) strains.
Phylogenetic analysis of the recA gene subdivides B. cenocepa-
cia into four distinct subgroups (141), with subgroup IIIA con-
taining the ET12 epidemic strain, associated with “cepacia
syndrome” (54), clinical deterioration, increased mortality (44,
57), and the ability to superinfect over existing B. multivorans
lung infection (84). Virulence markers, such as the B. cepacia
epidemic strain marker and the B. cenocepacia island (CCI),
are more frequently associated with B. cenocepacia IIIA strains
than other B. cenocepacia recA subgroups (10). In addition,
ET12 isolates possess the cable pilus (83, 137). Unlike other B.
cenocepacia subgroups, which can frequently be recovered
from the natural environment (31, 70), very few environmental
B. cenocepacia IIIA strains have been described (8), suggesting
a definite shift from a soil saprophyte to host-associated patho-
gen lifestyle.
The genome of B. cenocepacia strain J2315, a multidrug-
resistant CF patient isolate belonging to the ET12 lineage (44,
100), has been sequenced. The genomic analysis of B. cenoce-
pacia J2315 provides insights into the success of this strain and
how the ET12 lineage appears to have recently adapted to its
clinical niche in human infection.
MATERIALS AND METHODS
Bacterial strains. B. cenocepacia strain J2315 (CF5610) was isolated in 1989
from the sputum of a CF patient in Edinburgh, who was the United Kingdom
index case of the highly transmissible ET12 lineage (44). J2315 is resistant to the
aminoglycosides amikacin and tobramycin, the macrolide azithromycin, the
-lactams imipenem and piperacillin, and cotrimoxazole (trimethoprim-sulfame-
thoxazole) and also exhibits intermediate resistance to the fluoroquinolone cip-
rofloxacin. Strain J2315 has been deposited as LMG 16656 in the BCCM/LMG
Bacteria Collection.
Additional B. cenocepacia strains used in the present study were K56-2*,
BC7*, LMG 13307 (BCC0162), CEP0791 (BCC0077), LMG 13320 (BCC0179),
FC0504 (BCC0313), LMG 18827* (BCC0016), BCC1261, CEP0826 (BCC0222).
(An asterisk [*] indicates strains that are part of the published BCC strains panel
[81]). All strains had previously been sequence typed (9).
Genome sequencing. (i) Whole-genome sequencing. Strain J2315 was grown,
and DNA was extracted exactly as described previously (82). Sequence data were
obtained from 215,165 end sequences (giving approximately 11.9-fold coverage)
derived from m13mp18 and pUC18 genomic shotgun libraries (with insert sizes
of 1 to 6 kb) using BigDye terminator chemistry on ABI 3700 automated se-
quencers. A total of 4,300 end sequences from a large insert bacterial artificial
chromosome library (with insert sizes of 10 to 20 kb) were used as a scaffold. All
identified repeats were bridged by read-pairs or end-sequenced PCR products.
The sequence was annotated by using Artemis software (112). Initial coding
sequence (CDS) predictions were performed by using Orpheus (40), Glimmer2
(34), and EasyGene (69) software. These predictions were amalgamated, and
codon usage, positional base preference methods, and comparisons to the non-
redundant protein databases using BLAST (4) and FASTA (106) software were
used to refine the predictions. The entire DNA sequence was also compared in
all six reading frames against UniProt, using BLASTX (4) to identify any possible
CDSs previously missed. Protein motifs were identified by using Pfam (12) and
Prosite (37), transmembrane domains were identified with TMHMM (65), and
signal sequences were identified with SignalP version 2.0 (98). rRNAs were
identified by using BLASTN (4) alignment to defined rRNAs from the EMBL
nucleotide database; tRNAs were identified by using tRNAscan-SE (75); stable
RNAs were identified by using Rfam (46).
(ii) Comparative genomics. Comparison of genome sequences was facilitated
by using Artemis Comparison Tool (22), which enabled visualization of BLASTN
and TBLASTX comparisons (4). Orthologous proteins were identified as recip-
rocal best matches by using FASTA (106) with manual curation. Pseudogenes
had one or more mutations that would prevent correct translation; all inactivat-
ing mutations were checked against original sequencing data.
The J2315 genome was compared to B. vietnamensis strain G4 (accession
numbers CP000614, CP000615, and CP000616) (97), B. contaminans strain 383
(CP000151, CP000152, and CP000153) (127, 141), B. ambifaria strain AMMD
(CP000440, CP000441, and CP000442) (26), B. cenocepacia strains AU1054
(CP000378, CP000379, and CP000380) (http://genome.jgi-psf.org/finished
_microbes/burca/burca.home.html) and HI2424 (CP000458, CP000459, and
CP000460) (70), B. pseudomallei strain K96243 (BX571965 and BX571966) (51),
B. mallei strain ATCC 23344 (CP000010 and CP000011) (99), B. thailandensis
strain E264 (CP000086 and CP000085) (148), B. xenovorans strain LB400
(CP000270, CP000271, and CP000272) (23), and Ralstonia solanacearum strain
GMI1000 (118).
PCR screening. PCR amplification was performed by using Platinum Pfx DNA
polymerase (Invitrogen) according to the supplied protocols, with the optional
addition of 1/10 enhancer solution. Amplification consisted of 94°C for 10 min,
followed by 40 cycles of 94°C for 30 s, a suitable annealing temperature for 30 s,
and 68°C for 1 min per kb. A final extension of 10 min at 68°C was used. The
primers, along with the annealing temperature(s) used, were as follows:
BCAL3125 (AATCGGAACAGGTTGCACTC and AAACTGGAATGCGAA
GATGC), 60°C; BCAL3223 (ACCGATGTCTTCCTGTTTGG and AGCGGA
TGGTTCTTGATGAC), 60 to 68°C; BCAL3517 (GCACGTTGATTGTTTCT
TTGC and AATCGGGATCGACCTTGAC), 63 to 68°C; BCAM0856 (TCGA
AATACTTGTGCGCTTG and ACAGGAAGTGGTAGCCGATG), 68°C; and
BCAM2228 (GAACCTGACGGTGCTGAAC and GTAGACGGACAGGTCG
AAGC), 68°C.
EMBL accession numbers. The sequence and annotation of the B. cenocepacia
strain J2315 genome have been deposited in the EMBL database under accession
numbers AM747720, AM747721, AM747722, and AM747723.
RESULTS
General features of the J2315 genome. The complete ge-
nome of B. cenocepacia strain J2315 consists of three circular
chromosomes of 3,870,082, 3,217,062, and 875,977 bp and a
plasmid of 92,661 bp (Fig. 1). These four replicons encode
3,537, 2,849, 776, and 99 predicted CDSs, respectively (for a
summary of the features of the replicons, see Table 1), of
which 126 are pseudogenes or partial genes. Identification of
essential genes on chromosomes 2 and 3 led to designation
of these components of the genome as chromosomes rather
than megaplasmids.
Inter-replicon comparisons revealed very little extended
similarity except in the regions of the rRNA clusters (data not
shown). Intrareplicon comparison revealed that chromosome 1
contains a 57-kb perfect duplication (BCAL0969 to BCAL1026
and BCAL2901 to BCAL2846). The duplicated regions are at
different locations on the chromosome, and each contains 57
CDSs, leading to an increase in the gene dosage of CDSs that
encode a diverse collection of functions, including molybdop-
terin biosynthesis proteins, RNase E, ribosomal protein, fatty
acid/phospholipid synthesis proteins, sigma-E factor and regu-
lon, GTP-binding protein LepA, signal peptidase I, RNase III,
DNA repair protein RecO, elongation factor P, and CDP-
diacylglycerol–glycerol-3-phosphate 3-phosphatidyltransferase.
Analysis of the predicted functions of the CDSs on the
chromosomes revealed distinct partitioning of functions, as has
been previously seen in other Burkholderiaceae (51): chromo-
some 1 contains a higher proportion of CDSs involved in core
functions (cell division, central metabolism, and other “house-
keeping” functions), whereas chromosomes 2 and 3 contain a
greater proportion of CDSs encoding accessory functions, such
as protective responses and horizontal gene transfer, and a
greater proportion of CDSs with unknown functions (Fig. 2).
Comparative genomics. The J2315 genome was compared to
five other complete BCC genomes in the public databases:
Burkholderia vietnamiensis strain G4, an aromatic hydrocarbon
degrading environmental isolate (97); Burkholderia contami-
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nans strain 383, a soil isolate (127, 141); Burkholderia ambifaria
strain AMMD, a plant-associated biocontrol strain (26); and B.
cenocepacia IIIB strains AU1054 (http://genome.jgi-psf.org
/finished_microbes/burca/burca.home.html) and HI2424 (70),
isolated from a CF patient and soil, respectively. Both of these
B. cenocepacia strains are representatives of the B. cenocepacia
PHDC clonal lineage (25) that is widely distributed in the
United States (71). In addition, the genomes of four other
Burkholderia species were compared: Burkholderia pseudoma-
llei (51) and Burkholderia mallei (99), biothreat agents that
cause melioidosis and glanders, respectively; Burkholderia thai-
landensis (148), a soil saprophyte related to B. pseudomallei
and B. mallei; and Burkholderia xenovorans (23), a nonpatho-
genic soil isolate that degrades polychlorinated biphenyl (PCB)
FIG. 1. Schematic circular diagrams of the B. cenocepacia J2315 genome. The circular diagrams for chromosomes 1 (A) and 2 (B) are drawn
to scale, whereas those for chromosome 3 (C) and plasmid pBCJ2315 (D) are not drawn to scale. Black circles representing these replicons are
drawn to scale. The key for the three chromosomal circular diagrams (A, B, and C; outside to inside), with scale in Mb, is as follows. Annotated
CDSs are colored according to the predicted function represented on a pair of concentric circles, representing both coding strands. CDSs in
genomic island regions are indicated in green, and other RODs defined by pairwise genome comparisons with other BCC are indicated in red.
CDSs with matches identified by reciprocal FASTA with other Burkholderia species—B. cenocepacia HI2424, B. cenocepacia AU1054, B.
contaminans 383, B. ambifaria AMMD, B. vietnamiensis G4, B. xenovorans LB400, B. pseudomallei K96243, and B. thailandensis E264—are
indicated in dark blue. Orthologues shared with Ralstonia solanacearum GMI1000 are indicated in purple. For the GC content plot, the GC bias
(GC/GC) is indicated as 1% in khaki and 1% in purple. (D) The key for the circular diagram for plasmid pBCJ2315 is as described for
the chromosomes but lacks the orthologue matches. Color coding for CDS functions: dark blue for pathogenicity/adaptation, black for energy
metabolism, red for information transfer, dark green for surface associated, cyan for degradation of large molecules, magenta for degradation of
small molecules, yellow for central/intermediary metabolism, pale green for unknown, pale blue for regulators, orange for conserved hypothetical,
brown for pseudogenes, pink for phage and IS elements, and gray for miscellaneous.
VOL. 191, 2009 GENOME OF THE CF PATHOGEN BURKHOLDERIA CENOCEPACIA 263
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compounds. Ralstonia solanacearum (118), a plant pathogenic
member of the Burkholderiaceae, was also included as an
outlier.
The number of orthologous CDSs identified by best recip-
rocal FASTA in the genome of J2315 correlated with taxo-
nomic relatedness (Fig. 3) (141); the largest number of or-
thologs were identified in the BCC (78 to 63% of total CDSs),
followed by other Burkholderia species (56 to 50%), and Ral-
stonia solanacearum (37%). The distribution of orthologs on
the different replicons is similar to that seen in other Burkhold-
eria species, where the level of orthology is greatest on the
largest chromosome, with the secondary chromosomes being
progressively more divergent (51). The relative diversity of the
chromosomes was also evident in pairwise alignments that
illustrate regions of similarity and the overall genome struc-
ture. A comparison of concatenated genomes of B. cenocepacia
J2315, B. pseudomallei K96243, and B. xenovorans LB400
shows that, of all the chromosomes, chromosome 1 displays the
greatest level of conservation, both in the number and the
order of matches (see Fig. S1 in the supplemental material).
The largest chromosomes of these three Burkholderia species
contain colinear and inverted blocks of similarity, suggesting
that these replicons have undergone several rearrangement
events since they diverged from a common ancestor. The sec-
ond chromosome exhibits lower levels of overall conservation.
Although there are matches between the third chromosomes
of B. cenocepacia and B. xenovorans (the genome of B.
pseudomallei only contains two replicons), there is no detect-
able conservation of gene order.
RODs in the B. cenocepacia J2315 genome. Pairwise genome
comparisons of the B. cenocepacia strain J2315 genome to the
other B. cenocepacia strains identified regions of difference
(RODs) comprising ca. 21% of the DNA in J2315. These
include genomic islands (Table 2 and Fig. 1) that are likely to
have arisen from recent horizontal gene transfer (9.3% of the
chromosomal DNA) and encompasses mobile genetic ele-
ments (MGEs). In addition to the genomic islands, the J2315
genome contains 79 insertion sequence (IS) elements (Table 1
and see Table S1 in the supplemental material). Genomic
islands were defined as regions displaying anomalies in %GC
content or dinucleotide frequency signature (which is indica-
tive of very recent lateral transfer) and/or contained CDSs with
FIG. 2. Relative distribution of CDSs belonging to different functional classes on the three chromosomes of B. cenocepacia J2315. Figures for
the distribution of the functional classes on a chromosome are expressed as a ratio of the number of CDSs of a class per replicon against the total
number CDSs for that class in the genome, normalized per number of CDS on that replicon.
TABLE 1. General properties of the B. cenocepacia J2315 genome
Propertya Chromosome 1 Chromosome 2 Chromosome 3 Plasmid Total
Size (bp) 3,870,082 3,217,062 875,977 92,661 8,055,782
GC content (%) 66.7 67.9 67.9 62.6 66.9
No. of CDSs 3,537 2,849 776 99 7,261
Coding (%)* 86.1 86.4 86.0 78.6 85.9
Avg gene length (bp)* 958 985 986 763 970
rRNA 4 (16S-23S-5S) 1 (16S-23S-5S) 1 (16S-23S-5S) 0 6 (16S-23S-5S)
tRNA 66 6 2 0 74
Miscellaneous RNA 15 3 2 1 21
Pseudogenes and partial genes 56 41 23 6 126
IS elements 51 16 11 1 79
a *, Values exclude pseudogenes and partial genes.
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similarities to genes associated with MGEs such as bacterio-
phages, transposons, and plasmids. Boundaries of genomic is-
lands were mapped by using comparative genomic analysis.
Other RODs in the J2315 genome (11.7% of the chromosomal
DNA) include indel regions that represent lineage-specific
DNA insertions or deletions and allelic variants that have
divergent sequences at the same locus (Fig. 1). For the purpose
of our analysis, we have not included RODs that do not include
at least one complete CDS. Although these other RODs were
identified as being unique in comparison to B. cenocepacia
strains AU1054 and HI2424, many of these regions are ances-
tral regions that have been deleted in the other B. cenocepacia
genomes relative to J2315 and the other BCC. For example, if
B. contaminans strain 383 is included in the comparison, the
unique component of the J2315 genome falls to 7.0% (see
Table S2 in the supplemental material).
The ET12 lineage of B. cenocepacia emerged recently and
proved very successful at spreading between patients and caus-
ing disease (83). A possible contributory factor in its rise could
be the horizontal transfer of DNA. Fourteen regions in the
J2315 genome were identified as putative genomic islands (Ta-
ble 2), all fourteen of which are absent from the genomes of B.
cenocepacia AU1054 and HI2424.
The CCI, identified in the J2315 genome as genomic island
11 (BcenGI11; Table 2), has been shown to play a role in
infection (10, 84). When originally described, comparative
analysis of other BCC genomes was not available to allow the
boundaries of the island to be accurately predicted. The cur-
rent analysis defines the CCI as a 44-kb region, 12 kb and six
CDSs larger than its original description (10). New functions
attributed to the island include arsenic resistance, antibiotic
resistance, ion and sulfate family transporter, and stress re-
sponse, in addition to the fatty acid metabolism, amino acid
transport and utilization, and various regulators that include
an N-acyl-homoserine lactone-dependent quorum-sensing sys-
tem originally described (10).
The genome also provides evidence that the pan genome of
B. cenocepacia encompasses elements that may circulate in the
wider bacterial population, as several of the genomic islands
are similar to elements identified in other Burkholderia species.
The J2315 genome contains at least five prophages, one of
which, BcenGI1, exhibits extended mosaic similarity to the
K96243 prophage in the B. pseudomallei K96243 genome
(BP_GI1; see Fig. S2A in the supplemental material) (51).
Comparative genomic analysis identified related genomic
islands that integrate at orthologous sites in different species.
BcenGI2 is a 16.4-kb genomic island that contains CDSs with
similarity to plasmid conjugal transfer proteins, suggesting that
it may be an integrated conjugative element (21). BcenGI2 is
integrated at a tRNAAla gene and has some similarity to an
island (BP_GI11) integrated at the orthologous site in the B.
pseudomallei K96243 genome (see Fig. S2B in the supplemen-
tal material). This locus may be a hot spot for the traffic of
related islands in Burkholderia.
Genomic inventory of a versatile pathogen. The recent ecol-
ogy of the ET12 lineage of B. cenocepacia is that of a human-
associated pathogen, and as such the genome of strain J2315
appears to be well equipped with functions associated with
virulence in the CF lung (for a summary, see Table 3). There
is also evidence in the genome of the wider host associations of
this species, underlying its environmental origins. Orthologous
matches to putative J2315 virulence factors were found in the
FIG. 3. Comparison of the distribution of B. cenocepacia J2315 orthologs. Orthologs were identified in the Burkholderiaceae genomes B.
cenocepacia HI2424, B. cenocepacia AU1054, B. contaminans 383, B. ambifaria AMMD, B. vietnamiensis G4, B. xenovorans LB400, B. pseudomallei
K96243, and B. thailandensis E264 and in Ralstonia solanacearum GMI1000. Orthologs were identified by best reciprocal FASTA with an identity
cutoff of 30% and a length of match cutoff of 80%. The percentages of matches for individual J2315 chromosomes and the total genome are plotted.
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other Burkholderia genomes investigated, which included en-
vironmental bacteria. For example, 80% of the J2315 viru-
lence functions have orthologous matches to other B. cenoce-
pacia strains, 74% have matches to B. contaminans strain
383, and 68% have matches to B. pseudomallei. Many of
these functions therefore represent Burkholderia-wide func-
tions, which may promote survival in challenging and complex
environments such as the soil and rhizosphere but may also
have utility in the CF lung. In addition, comparative analysis
has highlighted virulence determinants in variable regions of
the J2315 genome (Table 3 and see Table S2 in the supple-
mental material), suggesting that this strain may have supple-
mented its core virulence determinants with accessory viru-
lence functions to enhance its disease causing ability.
Exoenzymes. Exoenzymes produced by B. cenocepacia play
an important role in modulating host cell interactions. Two
secreted zinc metalloproteases, ZmpA and ZmpB (Table 3),
have been found to have proteolytic activity against a range of
host molecules and have been implicated in the virulence of B.
cenocepacia (29, 62, 63). Phospholipases are widely distributed
TABLE 2. Genomic islands of B. cenocepacia strain J2315a
Chromosome
and island
Size
(kb) Coordinates
Integration
site
No. of
integrases %GC D K Functional note(s)
Chromosome 1
BcenGI1 25.0 100361. . .125265 tRNA Arg 1 – (68.5) – – Prophage, contains a group II intron; similar to
K96243 from B. pseudomallei K96243
BcenGI2 16.4 188011. . .204429 tRNA Ala 1  (55.7) –  ICE element similar to GI11 in B. pseudomallei
K96243
BcenGI3 13.1 449978. . .463082  (56.5)   Miscellaneous island, possible remnant,
contains type I restriction modification
system (BCAL0414, BCAL0418, and
BCAL0420)
BcenGI4 4.2 1032360. . .1036537 tRNA Met 1  (42.8) –  Miscellaneous island, contains three CDSs of
possible plasmid origin; similar island in B.
vietnamiensis G4
BcenGI5 92.8 1222566. . .1315385 1  (60.3) –  Miscellaneous island, contains miscellaneous
metabolism, including glycosyltransferase
(BCAL1147), polysaccharide deacetylase
(BCAL1148), putative O-antigen acetylase
(BCAL1191), possible hydroxybenzoate
degradation components (BCAL1151 to
BCAL1162), fusaric acid resistance-family
transporter (BCAL1176 to BCAL1178), and
glycerate kinase (BCAL1181)
BcenGI6 34.2 1402882. . .1437088 tRNA Arg 1  (58.8) –  Miscellaneous island
BcenGI7 37.7 1728919. . .1766584 BCAL1558  (62.9) –  Prophage, Mu-like
BcenGI8 121.9 2738065. . .2859923 BCAL2601 1  (61.4) –  Miscellaneous island, contains miscellaneous
metabolism including D-lactate
dehydrogenase (BCAL2487) and putative
O-antigen acetylase (BCAL2519),
glutathione S-transferase (BCAL2539), 3-
isopropylmalate dehydratase (BCAL2542 and
BCAL2543), MFS transporter (BCAL2525
and BCAL2545), ABC transporter
(BCAL2573 to BCAL2576), and nitrilase
(BCAL2585)
BcenGI9 16.3 3241588. . .3257909 tmRNA 1  (62.8) – – Miscellaneous island, phage origins, possible
phage remnant
BcenGI10 6.3 3368693. . .3375006 tRNA Gly 1  (59.4) –  Miscellaneous island, inserted into divergent
region
Chromosome 2
BcenGI11 44.1 290291. . .334378  (62.0) –  Cenocepacia island, contains arsenic resistance
(BCAM0233 to BCAM0235), antibiotic
resistance (BCAM0237A), ion and sulfate
family transporter (BCAM0238 and
BCAM0281), and stress response CDSs
(BCAM0276 and BCAM0278)
BcenGI12 46.8 1140183. . .1186975 tRNA SeC 1  (63.2) – – Prophage
BcenGI13 46.2 2091701. . .2137922 BCAM1874 1  (54.3) –  Prophage
Chromosome 3
BcenGI14 36.7 573207. . .609954 1  (62.8) – – Prophage BcepMu
a The number of putative integrases contained within islands is given. The presence () or absence (–) of anomalies in the properties of DNA within islands is
indicated in the columns marked %GC, D, and K, which represent the GC content, GC deviation, and the Karlin dinucleotide frequency signature, respectively.
The actual %GC for an island is indicated in parentheses in the %GC column.
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in bacteria and have been shown to mediate various cellular
functions, including membrane maintenance, cellular turnover,
and inflammatory response. Production of phospholipase C is
linked with CF isolates from patients of poor clinical status
(68). The J2315 genome encodes five homologs of Pseudomo-
nas aeruginosa phospholipase C proteins (Table 3). The redun-
dancy of these phospholipid-degrading enzymes suggests that
there is some functional specificity. To this end, studies of the
Plc-1 and Plc-2 phospholipases C from B. pseudomallei (ortho-
logues of which are present in the J2315 genome; BCAL1046
and BCAM2429, respectively) have demonstrated that al-
though they both hydrolyze phospholipid phosphatidylcholine
and sphingomyelin, they exhibit marked differences in their
cytotoxicity (64).
In addition to the five phospholipase C homologs the J2315
genome contains a putative phosphatidylinositol-specific phos-
pholipase C (PI-PLC; BCAM1969). Analysis of the taxonomic
distribution of proteins containing the PI-PLC domain
PF04185 reveals a very limited occurrence; among the gram-
negative bacteria, Burkholderia is the only genus within which
these proteins have been found, and among the gram-positive
bacteria, they have been found in an actinobacterium and some
firmicutes, including pathogenic bacilli, Staphylococcus aureus,
and Listeria monocytogenes (for the species distribution, see
http://pfam.sanger.ac.uk/family?accPF00388). In this latter
group of pathogens, PI-PLCs have been shown to have a role
in virulence (146, 149).
The J2315 genome also contains putative secreted pro-
teins similar to virulence factors produced by bacterial plant
pathogens associated with the degradation of plant tissue.
Two CDSs encode polygalacturonases, exoproteins that de-
grade pectin, a major component of plant cell walls;
BCAM2783 and BCAS0196 are 69.1 and 31.9% identical to
polygalacturonases from R. solanacearum (43) and Agrobac-
terium vitis (50), respectively. In addition to these degrada-
tive enzymes, the genome also contains a locus (BCAM0153
to BCAM0156) encoding additional pectin degradation
components.
TABLE 3. Potential virulence functions encoded in the genome of B. cenocepacia strain J2315
Function Notes and examples CDSsa
Exoproteins Zinc metalloproteases ZmpA and ZmpB BCAS0409 and BCAM2307
Phospholipases C BCAL0443; BCAL1046; BCAM0408*; BCAM1969; BCAM2429;
BCAM2720
Secretion Type I secretion (T1S) BCAM2140 to BCAM2142; BCAM1317 to BCAM1320
Type II secretion (T2S) BCAL3447 and BCAL3515 to BCAL3527
Type III secretion (T3S) BCAM2045 to BCAM2057
Type IV secretion (T4S) BCAM0324 to BCAM0340; pBCA020 to pBCA059
Type V secretion (T5S) BCAL3353; BCAM0183; BCAM2169; BCAS0321
Type VI secretion (T6S) BCAL0337 to BCAL0351
LPS and capsule LPS biosynthesis clusters: core, O-antigen and lipid
A modification
BCAL2402 to BCAL2408; BCAL3110 to BCAL3125;
BCAL1929 to BCAL1935
Cepacian polysaccharide synthesis and export
cluster
BCAM0854 to BCAM0865
Other potential surface polysaccharides
biosynthetic clusters
BCAL3217* to BCAL3246*; BCAM0203 to BCAM0214;
BCAM1003 to BCAM1011; BCAM1224 to BCAM1228;
BCAM1330* to BCAM1340*; BCAM2032* to BCAM2035*;
BCAS0294 to BCAS0297
Adhesins 22-kDa adhesion protein AdhA BCAM2143*
BuHA family proteins BCAM0219*; BCAM0223*, BCAM0224*; BCAM1115*;
BCAM2418; BCAS0236; BCAS0335; pBCA011*
Fimbriae and pili Cable pilus BCAM2756* to BCAM2762*
Chaperone-usher type fimbriae BCAL1677 to BCAL1680; BCAL1826 to BCAL1828;
BCAL2634a* to BCAL2637*
Flp-type pili BCAL1520 to BCAL1537; BCAS0298 to BCAS0312
Type IVa pilus BCAL0959, BCAL3445 to BCAL3447, BCAL0276 to
BCAL0278
Quorum sensing N-Acylhomoserine lactone regulons CepIR and
CciIR
BCAM1870 and BCAM1868; BCAM0239a* and BCAM0240*
N-Acylhomoserine lactone dependent regulator BCAM0188
Siderophores Ornibactin BCAL1688 to BCAL1702
Salicylic acid and pyochelin BCAM2224 to BCAM2235
Intracellular stress Natural resistance-associated macrophage proteins BCAM0836, BCAM1764, BCAM2060, BCAS0630 and
BCAS0634*
Superoxide detoxification: superoxide dismutases,
peroxidase/catalase, catalases, thiol peroxidase,
alkyl hydroperoxidase
BCAL2643 and BCAL2757; BCAL3299 and BCAM2107*;
BCAS0635 and BCAM0931; BCAL3424; BCAM1216 and
BCAM1217
Motility Nitric oxide detoxification, flavohaemoglobin BCAL3285
Five gene clusters on chromosome 1 encode the
components of a single flagellar system
BCAL0113 to BCAL0114; BCAL0140 to BCAL0144;
BCAL0520 to BCAL0527; BCAL0561 to BCAL0577;
BCAL3501 to BCAL3507
Two additional flagellar components on
chromosome 2 and chromosome 3
BCAM0987; BCAS0104
a An asterisk (*) indicates a gene or genes associated with that function that is absent from both B. cenocepacia AU1054 and HI2424 genomes.
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Secretion. Further evidence of the plant associations of B.
cenocepacia are found in the secretion systems. The J2315
genome encodes a type IV secretion system (T4SS) associated
with disease in plants; the plasmid-encoded T4SS (Table 3)
secretes plant cytotoxic proteins responsible for plant tissue
watersoaking (ptw) on onions (35). In addition, there is a
cluster on chromosome 2 (Table 3) that is similar to the ptw
cluster and other T4SSs. The function of this cluster (vir) is
unclear: mutants do not affect expression of the ptw phenotype.
The organization of the vir cluster is similar to that of the virB
clusters of Brucella abortus and Agrobacterium tumefaciens, al-
though it lacks homologues of virB5 and virB7. The cluster con-
tains two additional CDSs between the virB6 (BCAM0328) and
virB8 (BCAM0331) homologues, similar to traF (BCAM0329)
and traI (BCAM0330) components of the pSB102 plasmid con-
jugation system. These tra system components are functionally
equivalent to virB5 and virB7. It is unlikely that this cluster is
functional in J2315, since the virD4 homologue (BCAM0335)
contains a frameshift mutation.
The type III secretion system (T3SS; Table 3) is associated
with pathogenesis: mutants in the T3SS demonstrate reduced
virulence in a murine model of infection (132) and in a Cae-
norhabditis elegans killing assay (86). T3SSs have been shown
to be important in the intracellular survival of several patho-
gens; however, there is no evidence that this is the case in B.
cenocepacia: internalization and survival of J2315 T3SS mu-
tants in macrophages was the same as for the wild type (67).
There are four type V secretion (T5S) proteins in the ge-
nome (Table 3). Two of these autotransporters contain per-
tactin domains (Pfam PF03212; BCAL3353 and BCAM0183),
and the other two contain hemagglutinin repeat domains
(Pfam PF05594; BCAM2169 and BCAS0321).
The extensive array of secretion systems has further been
enhanced by the identification of a type VI secretion (T6S)
system on chromosome 2 (Table 3). Three T6S system clusters
have been identified in P. aeruginosa (33), one of which (HSI-I)
has been demonstrated to be essential in the chronic rat lung
infection model (108). HSI-I exports Hcp1, a hexameric pro-
tein that has been detected in pulmonary secretions of CF
patients, and Hcp1-specific antibodies detected their in sera
(93).
In contrast to the other pathogenic Burkholderia sequenced,
B. cenocepacia J2315 does not exhibit a large redundancy of
secretion systems. For example, B. mallei, and B. pseudomallei
possess four and six T6SSs, respectively (119), and two and
three T3SSs, respectively (51, 99).
LPS and exopolysaccharide (EPS). Lipopolysaccharide
(LPS) produced by B. cenocepacia has an important role in
both disease and resistance to antimicrobial peptides. The LPS
of the ET12 strain C1359 has been demonstrated to be endo-
toxic and to stimulate tumor necrosis factor production in
greater quantities than that of P. aeruginosa (121). Three clus-
ters in the J2315 genome are associated with the production of
the core (BCAL2402 to BCAL2408), O antigen (BCAL3110 to
BCAL3125) (101), and lipid A modification (BCAL1929 to
BCAL1935) of LPS. However, strain J2315 has lost its ability
to make complete LPS O antigen, due to an IS insertion in the
glycosyltransferase BCAL3125 (101).
The structure and composition of B. cenocepacia LPS con-
tributes to the intrinsic resistance to aminoglycoside (30, 91)
and polymyxin. The presence of 4-amino-4-deoxy-L-arabinose
moieties within the inner core region has been shown to reduce
the binding of cationic antibiotics such as polymyxin B to B.
cenocepacia LPS (74, 122). A locus on chromosome 1
(BCAL1929 to BCAL1935) is similar to a cluster of six CDSs
in E. coli and Salmonella that have been shown to direct the
transfer of 4-amino-4-deoxy-L-arabinose to lipid A in polymyxin-
resistant mutants (134). Interestingly, in pathogens such as
Salmonella, polymyxin B acts as an antagonist of LPS patho-
logical activity; however, in B. cenocepacia this antibiotic en-
hances its activity (122). A recent study showed that this cluster
is essential for the viability of B. cenocepacia and that a reduc-
tion in viability was accompanied by changes in cell morphol-
ogy (102).
A cluster associated with the production of cepacian (B.
cenocepacia-specific EPS) has been identified (Table 3) (92).
J2135 does not produce cepacian; a CDS (BCAM0856) in the
cluster contains a frameshift mutation (11-bp deletion). Al-
though J2315 is described phenotypically as nonmucoid (49),
the genome contains several other loci that encode putative
EPS-related functions (Table 3), suggesting that J2315 may
have the ability to produce capsular material under some en-
vironmental conditions. One of these clusters (BCAL3217 to
BCAL3246) (105) is similar to the capsular polysaccharide
cluster of B. pseudomallei K96243 (51), containing two regions
of similarity (BCAL3217 to BCAL3223 and BCAL3240 to
BCAL3246) separated by a block of divergent sequence
(BCAL3227 to BCAL3239). This cluster is probably not ex-
pressed in J2315 since it contains an IS element that disrupts a
putative capsule polysaccharide biosynthesis/export protein
(BCAL3223).
Pili, fimbriae, and adhesins. The adherence of pathogenic
bacteria to host cells is often associated with pili, fimbriae, and
adhesins. These surface-expressed structures can modulate in-
teractions with host cells and other bacterial cells and can
target cells to a site of infection. Members of the BCC possess
an array of different types of appendage pili: electron micros-
copy studies identified five morphologically distinct classes of
appendage pili in BCC strains (42).
The cable pilus is associated with the ET12 B. cenocepacia
lineage (130) and modulates binding to host molecules such as
cytokeratin 13 (116) and mucins (115) that are abundant in the
CF lung. The cable pilus gene cluster is located on chromo-
some 2 and consists of seven CDSs (Table 3), four of which
encode structural and processing components (cblDCAB) and
three of which encode regulatory components (cblRTS). The
pili are arranged as large peritrichous individual fibers 2 to 4
	m in length and are associated with a 22-kDa adhesion pro-
tein (AdhA) (137). Both the cbl cluster and adhA are in RODs,
as is one of the three chaperone-usher-type fimbria clusters
contained within the J2315 genome (Table 3). The first of
these clusters encodes a fimbrial protein (BCAL1677) similar
to the type I fimbrial protein FimA from E. coli (60). The other
two clusters do not contain homologs of characterized fimbrial
proteins, although both clusters contain exported proteins
(BCAL1826; BCAL2634a and BCAL2635) which may be fim-
brial components.
Type IV pili have been shown to modulate a variety of
processes, including adhesion, twitching motility, and biofilm
initiation and development (20). In B. pseudomallei a type IV
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pilin deletion mutant (pilA mutant) was attenuated in mouse
and nematode models of virulence (36). Type IV pili have also
been shown to play a role in the adherence of B. pseudomallei
to eukaryotic cells. Microcolony formation is a key process in
cell adherence—an ability reduced in pilA mutants (15). In P.
aeruginosa, type IV pili have been shown to bind to human
epithelial cells (53), as well as induce apoptosis (55). The
observation that these pili also bind DNA (143) suggests that
they may play an important role in the formation of biofilms in
the CF lung, where DNA is an abundant matrix molecule.
There are several loci in the J2315 genome that encode com-
ponents of a type IVa pilus, as well as two clusters that encode
Flp-type pili (Table 3) (58).
The J2315 genome contains eight BuHA family proteins
(Table 3), five of which are unique to J2315 and are present in
RODs (see Table S2 in the supplemental material). This family
of autotransporting membrane proteins contain a C-terminal
YadA domain, together with HIM and Hep_Hag domains, a
domain architecture that is shared with hemagglutinins and
invasins that mediate bacterial interactions with host cells or
extracellular matrix proteins. In B. mallei BuHA proteins ex-
pressed in vivo during experimental equine glanders infection
were found to be immunodominant (131). The distribution of
these proteins is widespread in gram-negative bacteria; how-
ever, the genomes of Burkholderia species, especially the
pathogenic members of the genus, contain greater numbers of
members of this family.
Iron metabolism. Iron is vital for life; however, much of the
iron in the human body is complexed by compounds such as
ferritin. In order for B. cenocepacia to survive in the host, iron
must be scavenged via the production and uptake of sid-
erophores. Biosynthesis clusters for ornibactin, salicylic acid
(SA), and pyochelin siderophores are present in the J2315
genome (Table 3). B. cenocepacia produce the iron-chelating
siderophores ornibactin, pyochelin, and SA in a strain-depen-
dent manner (145). Ornibactin has been shown to be the most
important of these in CF lung pathogenesis and consists of a
mixture of modified tetrapeptides with three different side
groups (128, 145). The ornibactin biosynthetic cluster is lo-
cated on chromosome 1 (1), whereas the SA and pyochelin
clusters are situated on chromosome 2 (111). The ability of
J2315 to produce pyochelin is compromised since the pyo-
chelin biosynthesis gene pchF (BCAM2230) contains a frame-
shift mutation. However, the genes encoding the transport and
utilization of pyochelin in J2315 are intact and therefore prob-
ably functional.
Motility. Flagella have been shown to play an important role
in the pathogenesis of B. cenocepacia, contributing to the in-
vasion of lung epithelial cells (133) and modulating the im-
mune response via the Toll-like receptor 5 (138). Five gene
clusters on chromosome 1 together encode the components of
a complete flagellum system (Table 3). Two duplicated com-
ponents of this system are encoded on the other replicons:
flagellar basal body protein FlgE2 (BCAM0987; paralog of
BCAL0567) and flagellar hook-associated protein FliD2
(BCAS0104; paralog of BCAL0113). In P. aeruginosa two dis-
tinct flagellar hook-associated proteins have been identified (6)
and shown to be antigenically distinct. In addition to being
structural components of the flagella, flagellar cap proteins
also bind mucin (7), an important initial event in the coloni-
zation of the CF lung. The additional copy of an antigenically
distinct fliD therefore provides J2315 with variants, which it
may use to evade the host immune system during the initial
stage of infection.
Stress response. Intracellular survival of BCC bacteria
within macrophages may contribute to bacterial persistence
within the lung and airways of patients with CF and to sus-
tained tissue inflammation (17, 87, 113). Resistance to oxida-
tive stress is often associated with the ability of bacterial patho-
gens to survival within macrophages. Two of the most potent
mechanisms utilized by activated macrophages to kill bacteria
involve the production of reactive oxygen and reactive nitrogen
oxide species. The detoxification of nitric oxide in Salmonella
enterica serovar Typhimurium involves the flavohemoglobin
HmpA (129), and the J2315 genome contains homologue of
hmpA (Table 3). The detoxification of superoxide requires
conversion of superoxide to hydrogen peroxide, encoded by
sod genes, followed by destruction of the hydrogen peroxide by
catalases, encoded by kat genes. The J2315 genome contains
homologues of sodB (BCAL2757), sodC (BCAL2643), katA
(BCAM2107), and katB (BCAL3299), as well as an additional
catalase (BCAM0931) and a manganese-containing catalase
(BCAS0635). There are also five NRAMP (natural resistance-
associated macrophage protein; Table 3) family proteins in the
genome. These divalent transition metal transporters are in-
volved in iron metabolism and play a role in bacterial response
to reactive oxygen species (59, 144).
Drug resistance. Strains of BCC exhibit high levels of anti-
biotic resistance, so much so that some BCC strains can use
penicillin G as a sole carbon source (14). The drug resistances
of strains infecting CF patients are often considered markers
of mortality and in this way are considered virulence factors. In
the BCC, resistance to multiple antibiotics is produced by
multiple mechanisms that include alterations in cell permeabil-
ity, the production of modifying or degradatory enzymes, and
antibiotic target alteration. Other mechanisms of resistance
may also be related to diminished antibiotic access (16), in-
cluding drug efflux (150). J2315 is resistant to the aminoglyco-
sides amikacin and tobramycin, the macrolide azithromycin,
the -lactams imipenem and piperacillin, and cotrimoxazole
(trimethoprim-sulfamethoxazole). The strain also exhibits in-
termediate resistance to the fluoroquinolone ciprofloxacin.
Resistance to the -lactam antibiotics appears to be caused
by synergistic mechanisms, including the induction of chromo-
somal -lactamases (109, 135) and decreased drug access (5,
104). There are at least four -lactamases encoded in the J2315
genome, including: two class A, one class C, and one class D
(Table 4). In addition, there are several -lactamase family
proteins containing -lactamase Pfam domains (PF00144) that
may have antimicrobial resistance functions.
Efflux systems can modulate broad-spectrum antibiotic re-
sistance, as well as resistance to specific antimicrobial com-
pounds. Multiple transport systems belonging to six families
associated with drug resistance were identified in the J2315
genome: MFS (major facilitator superfamily), ABC (ATP
binding cassette) family, RND (resistance nodulation division)
family, MATE (multidrug and toxic compound extrusion) fam-
ily, SMR (small multidrug resistance) family, and fusaric acid
resistance family proteins (Table 4). Some of these families
have many members in the J2315 genome; however, it is un-
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clear from in silico analysis alone whether or not they play a
role in antibiotic resistance. For example, 16 CDSs were iden-
tified in the J2315 genome that encode efflux pumps belonging
to the RND family. Two of these CDSs belong to systems that
have been shown to be associated with drug resistance in B.
cenocepacia: BCAM2550 (ceoB) is a component of a system
that encodes chloramphenicol, trimethoprim, and ciprofloxa-
cin resistance (19, 95), and BCAS0765 is associated with resis-
TABLE 4. Potential drug resistance determinants in the genome of B. cenocepacia strain J2315
Gene product CDSsa Resistance Reference
Chromosome 1
RND family efflux transporter BCAL1079 to BCAL1081 Unknown 94
Fusaric acid resistance family transporter BCAL1176* to BCAL1178* Unknown 139
Fosmidomycin resistance protein BCAL1451 Fosmidomycin 41
Fusaric acid resistance family transporter BCAL1453 to BCAL1456 Unknown 139
MFS efflux transporter BCAL1510 to BCAL1512 Unknown 73
RND family efflux transporter BCAL1674 to BCAL1676 Aminoglycosides 2, 90
RND family efflux transporter protein BCAL1778 Unknown
RND family efflux transporter BCAL1811 to BCAL1813 Unknown
MATE family multidrug resistance protein BCAL1907 Unknown
RND family efflux transporter BCAL2134 to BCAL2136 Unknown
RND family efflux transporter BCAL2820 to BCAL2822 Unknown 77
MATE family multidrug resistance protein BCAL2907 Polymyxin B 38
Dihydrofolate reductase BCAL2915 Trimethoprim 18
Tetracycline resistance protein, class C
(pseudogene)
BCAL3259 Tetracycline 3
MFS efflux transporter BCAL3511 and BCAL3514 Unknown, lacks HylD family
component
73
Chromosome 2
MFS efflux transporter BCAM0199 to BCAM0201 Unknown
MarC family protein BCAM0237A Unknown 28
-Lactamase, class D BCAM0393 -Lactams 107
RND family efflux transporter BCAM0925 to BCAM0927 Aminoglycosides 78
Aminoglycoside 3
-phosphotransferase BCAM0928* Aminoglycosides 13
Aminoglycoside-3
’-adenylyltransferase BCAM1013A* Aminoglycosides 52
MFS efflux transporter protein BCAM1132* Unknown
MFS efflux transporter protein BCAM1202 Unknown
MFS efflux transporter protein
(pseudogene)
BCAM1251 Unknown
RND family efflux transporter BCAM1419 to BCAM1421 Unknown
Fusaric acid resistance family transporter
protein
BCAM1452 Unknown 139
MarC family protein BCAM1709 Unknown 28
Fusaric acid resistance family transporter
protein
BCAM1758 Unknown 139
MFS efflux transporter protein BCAM1760 Unknown
-Lactamase, class A BCAM1779 Ceftazidime, clavulanic acid 136
Putative multidrug efflux system
transporter
BCAM1864 to BCAM1866 Unknown
RND family efflux transporter BCAM1945 to BCAM1947 Olaquindox 48
-Lactamase, class A BCAM2165 -Lactams 135
Macrolide-specific efflux system
transporter
BCAM2186 to BCAM2188 Macrolides 61
MFS efflux transporter BCAM2334, BCAM2335, and
BCAM2337
Unknown
Rifampin ADP-ribosyl transferase BCAM2385 Rifampin 110
RND family efflux transporter BCAM2549 to BCAM2551 Chloramphenicol, trimethoprim, and
ciprofloxacin
19, 95
Streptomycin 3
-kinase BCAM2633 Aminoglycosides 88
Chromosome 3
Fusaric acid resistance family transporter
protein
BCAS0014 to BCAS0017 Unknown 139
-Lactamase, class C BCAS0156 -Lactams 85
MFS efflux transporter protein BCAS0289 Unknown
Putative glutathione transferase BCAS0336* fosfomycin 96
MFS efflux transporter BCAS0471 to BCAS0473 Unknown
RND family efflux system transporter BCAS0582 to BCAS0584 Unknown
RND family efflux system transporter BCAS0591 to BCAS0593 Unknown
RND family efflux system transporter BCAS0764 to BCAS0766 Aminoglycosides gentamicin and
streptomycin, macrolide erythromycin
24, 47
a An asterisk (*) indicates a gene(s) is associated with that function but absent from both B. cenocepacia AU1054 and HI2424 genomes.
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tance to the antibiotics fluoroquinolones, tetraphenylphospho-
nium, and streptomycin, as well as to ethidium bromide (47).
In addition, the genome contains orthologues of RND efflux
proteins that have been shown to mediate resistance to anti-
biotics (2, 77, 78, 90, 94), metals (39, 66, 103), and other
antimicrobial compounds (48) in other organisms.
Comparisons with other sequenced strains show that the
J2315 genome contains strain-specific CDSs (Table 4) that may
contribute to its elevated drug resistance, for example: a pu-
tative fusaric acid efflux system, RND family efflux systems, an
aminoglycoside 3
-phosphotransferase, and a multiple antibi-
otic resistance protein.
Evolution of virulence in the ET12 lineage. Considering the
pathogenic pedigree of J2315, it was surprising that several
virulence determinants that have been shown to be important
for B. cenocepacia pathogenicity were pseudogenes in J2315
(Table 5). In order to discover how widely distributed these
mutations were we screened five of the virulence factor pseu-
dogene loci in B. cenocepacia strains. Multilocus sequence typ-
ing was used to select strains as it proved additional resolution
for distinguishing strains within, and related to, the ET12 lin-
eage (Table 6) (9). Four strains belonging to the same se-
quence type (ST) as J2315 (ST28) were screened, along with
two other closely related strains (BCC0016 and K56-2) that are
single and double locus variants of ST28 (ST29 and ST30,
respectively; http://pubmlst.org/bcc).
Screening of the virulence pseudogenes revealed the likely
relative timescales of acquisition of these mutations. For ex-
ample, pseudogenes that disrupt pyochelin biosynthesis and
cepacian capsule functions were identified in all of the ET12
strains tested (Table 6), suggesting that they occurred in an
ancestral strain, whereas the O-antigen cluster, T2SS, and un-
characterized EPS cluster pseudogenes were intermittently dis-
tributed, indicating that they are recent mutational events.
The observation of independent mutations in the ET12
strain K56-2 uncharacterized EPS CDS suggests ongoing se-
lection for the loss of this potential virulence function in the
CF lung. There is further evidence for pathoadaptation involv-
ing exopolysaccharide structures in the PHDC lineage of B.
cenocepacia (i.e., strains AU1054 and HI2424). In the B. ceno-
cepacia IIIB strains there are divergent clusters at orthologous
loci for the LPS O antigen and EPS. In AU1054, both of these
clusters are disrupted by IS element insertions, whereas the
HI2424 clusters remain intact.
The modification of core functions via point mutation has
also contributed to drug resistance in J2315. Trimethoprim
interferes with the action of bacterial dihydrofolate reductase
(DfrA), inhibiting synthesis of the essential tetrahydrofolic
acid. Members of the ET12 lineage exhibit different sensitivi-
ties to trimethoprim (100). To investigate the evolution of
trimethoprim resistance in the ET12 lineage, we sequenced
dfrA from members of this clonal group that have different
trimethoprim MICs (K56-2 and BCC0179, MIC  2 mg/liter;
J2315, BCC0016, and BC7, MIC  32 mg/liter). J2315,
BCC0016, and BC7 all contain a single nonsynonymous nucle-
otide substitution at codon 99 (CTC to ATC), resulting in a
leucine-for-isoleucine substitution. In an experiment with E.
coli mutator strains exposed to antibiotics, resistance to tri-
methoprim was shown to be the result of a single point muta-
tion in DfrA, Ile94 to Leu, for which the equivalent residue in
B. cenocepacia is exactly Ile99/Leu99 (89).
DISCUSSION
B. cenocepacia is a versatile environmental organism that has
emerged as an important pathogen of CF patients. Using the
J2315 genome we have been able to investigate the genomic
basis for the success of this CF pathogen and examine the
evolutionary mechanisms that may lead to its emergence and
ongoing spread.
Comparative analysis of Burkholderia genomes reveals that
horizontal gene transfer has contributed to the genomic plas-
ticity of this versatile group of organisms. The exchange of
MGEs and movement of genomic islands facilitates the spread
of genes between genetically diverse bacteria, a process which
could be advantageous to the bacterium in its existing environ-
ment or allow adaptation to new niches, such as the CF lung.
The J2315 genome contains 14 genomic islands that are absent
from the other B. cenocepacia strains. Some of the islands
share similarity with islands in other Burkholderia spp., sug-
gesting that the extent of the B. cenocepacia pan genome ex-
tends well beyond that of the species. The acquisition of
genomic islands appears to have been seminal in the evolution
of the ET12 lineage, introducing functions that promote sur-
vival and pathogenesis in the CF lung. One such island is the
CCI (BcenGI11). This island plays a role in infection, is ubiq-
uitous in the ET12 lineage, and is more common in B. ceno-
cepacia IIIA strains than IIIB (10, 84). The contribution of the
other genomic islands to the virulence and survival of J2315 in
the CF lung remains to be resolved, since many of the func-
tions encoded in the genomic islands are associated with
enhancing the metabolic repertoire of the bacterium or are
unknown.
Evidence of the pathogenic specialization of the ET12 lin-
eage can be found in the other RODs. These regions do not
appear to have the properties of MGEs and as such represent
more stable components of the J2315 genome, albeit some may
have arisen by horizontal gene transfer in the more distant
past. Contained within this unique component of the J2315
genome are the cable pilus locus and the 22-kDa adhesion
protein AdhA. These proteins bind cytokeratin 13 (116), a
cytoplasmic protein that may become surface exposed during
the course of chronic infection in CF (114), and also mucins
(115), which are produced in abundance in the CF lung due to
poor clearance. The cable pilus/AdhA complex is also associ-
ated with the ability of B. cenocepacia to bind to CF lung
explant tissue (114) and bind and invade epithelial cells (117).
Intriguingly, the CDSs encoding these components are at sep-
arate loci on chromosome 2, and orthologs are absent from the
other BCC strains examined. This suggests that the pilus and
the 22-kDa adhesin may have independent origins, but their
concurrence in J2315 has resulted in functional synergy. Other
virulence functions found within the J2315-specific RODs
include surface polysaccharide biosynthesis, BuHA family
putative adhesins, chaperone-usher type fimbriae, and a phos-
pholipase C.
In recent years B. cenocepacia strains have acquired addi-
tional resistances to antibiotics commonly used in the treat-
ment of CF patients. In particular, strains from within the
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ET12 lineage have different sensitivities to ciprofloxacin, to-
bramycin, tetracycline, and trimethoprim (100). In comparison
to other members of the ET12 lineage, J2315 has developed
enhanced resistance to a number of antibiotics (100). Indeed,
we found that the J2315 genome contains drug resistance in
genomic islands and RODs, highlighting the role that horizon-
tal gene transfer has played in the evolution of drug resistance
in even the most intrinsically resistant of organisms. The ge-
TABLE 5. Pseudogenes in the genome of B. cenocepacia J2315
Chromosome and gene product CDSs Mutation type
Chromosome 1
Gly/Ala/Ser-rich lipoprotein BCAL0138 Nonsense (amber)
Type I modification component of restriction-modification system BCAL0414 Disruption, IS element
Putative transferase BCAL0648 Frameshift
Putatve PTS system, EIIA 2 component BCAL0810 Nonsense (amber)
UvrABC system protein C 2 BCAL1014 Disruption, IS element
Putative transposase BCAL1028 Nonsense (amber) and frameshift
IclR family regulatory protein BCAL1082 Nonsense (ochre)
Conserved hypothetical protein BCAL1124a Disruption, IS element
Conserved hypothetical protein BCAL1132 Disruption, IS element
Conserved hypothetical protein BCAL1169 Disruption, IS element
Conserved hypothetical protein BCAL1302 Disruption, IS element
Putative SNF2-related helicase BCAL1308 Disruptions, IS elements
Putative oxidoreductase BCAL1558 Disruption, prophage
TetR family regulatory protein BCAL1672 Frameshift
TonB-dependent receptor BCAL1783 Nonsense (amber)
Putative DNA-binding protein BCAL2066 Frameshift
Hypothetical protein BCAL2219 Disruption, IS element
Conserved hypothetical protein BCAL2279 Disruption, IS element
Putative ATP-dependent DNA helicase BCAL2480 Disruption, IS element
Putative transposase BCAL2496 Disruption, IS element
Putative methionine aminopeptidase BCAL2533 Disruption, IS element
Conserved hypothetical protein BCAL2574 Nonsense (amber)
Putative transposase-related protein BCAL2581 Frameshift
Conserved hypothetical protein BCAL2591 Disruption, IS element
ABC transporter ATP-binding protein BCAL2601 Frameshift and deletion
UvrABC system protein C1 BCAL2854 Disruption, IS element
Glycosyltransferase BCAL3125 Disruption, IS element
Putative capsule polysaccharide biosynthesis/export protein BCAL3223 Disruption, IS element
Putative transposase BCAL3248 Disruption, IS element
Putative transposase BCAL3249 Disruption, IS element
Tetracycline resistance protein, class C BCAL3259 Frameshift
Glutamate/aspartate ABC transporter ATP-binding protein GltL BCAL3354 Frameshift
General secretory pathway protein L BCAL3517 Frameshift
Chromosome 2
Putative pyridoxal-dependent decarboxylase BCAM0245 Disruption, IS element
Conserved hypothetical protein BCAM0274a Frameshift
Putative conjugal transfer protein BCAM0335 Frameshift
Putative acetyltransferase–GNAT family BCAM0354a Frameshifts
AraC family regulatory protein BCAM0454 Frameshift
Conserved hypothetical protein BCAM0520 Disruption, IS element
TonB-dependent receptor BCAM0706 Frameshift
Conserved hypothetical protein BCAM0788 Frameshift
Undecaprenyl-phosphate glucosyl-1-phosphate transferase BCAM0856 Frameshift
Major Facilitator Superfamily protein BCAM1102 Nonsense (amber)
Putative multidrug resistance transporter BCAM1251 Disruption, IS element
Conserved hypothetical protein BCAM1328 Frameshifts
Amino acid permease BCAM1498 Frameshift
Putative short-chain dehydrogenase BCAM1794 Nonsense (amber)
Putative GTP cyclohydrolase II BCAM1874 Disruption, prophage
Hypothetical phage protein BCAM1914 Disruption, IS element
Phage integrase BCAM1923 Disruption, IS element
Putative plasmid stability protein BCAM2006a Frameshift
Putative plasmid stability protein BCAM2006b Frameshift
Conserved hypothetical protein BCAM2043 Frameshift
Conserved hypothetical BCAM2101 Disruption, IS element
Putative pyochelin synthetase PchF BCAM2228 Frameshift
Putative porin-related protein BCAM2621 Nonsense (opal)
Two-component regulatory system, response regulator protein BCAM2837 Frameshift
Chromosome 3
Conserved hypothetical protein BCAS0180 Frameshift
ABC transporter ATP-binding protein BCAS0221 Frameshift
ABC transporter ATP-binding protein BCAS0421 Disruption, IS element
cis-1,2-Dihydroxycyclohexa-3,5-diene-1-carboxylate dehydrogenase BCAS0493 Frameshift
Putative short chain dehydrogenase BCAS0644 Frameshifts
Putative short chain dehydrogenase BCAS0645 Frameshifts
LysR family regulatory protein BCAS0646 Frameshift
Putative transposase BCAS0651 Disruption, IS element
Putative transposase BCAS0681 Disruption, IS element
Plasmid
Putative hemagglutinin-related autotransporter protein pBCA011 Frameshift
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nome also provides evidence for the evolution of drug resis-
tance through point mutation, elucidating a nonsynonymous
base change in the dihydrofolate reductase gene that generates
trimethoprim resistance.
Although the success of J2315 may be in part due to the
acquisition of new functions, gene loss via mutation appears to
have also played an important role. J2315 is a formidable
pathogen of the CF lung; once infected with ET12, the life
expectancy of a patient shortens dramatically (57). It is there-
fore surprising that the J2315 genome contains pseudogenes,
formed via both IS disruption and frameshift mutations, in
important B. cenocepacia virulence functions, such as O anti-
gen and capsule (Table 6). Many of the putative virulence
determinants identified in J2315 are shared with other BCC
strains. These functions may therefore have important roles for
the survival of BCC in its natural reservoir rather than in an
opportunistic pathogen niche. In the case of J2315, the emer-
gence and patient-to-patient spread of ET12 may mean that
many of the functions required for survival in the environment
are no longer required and have become superfluous or even
disadvantageous. The level of pseudogenes and partial genes in
the J2315 genome (1.7% of CDSs) is similar to the level found
in most other bacterial genomes (72), suggesting that there is
not an elevated level of mutation in this strain.
The screening of the virulence pseudogenes in other ET12
strains showed that some of the J2315 mutations may have
occurred early on in the evolution of the ET12 lineage,
whereas others represent recent strain-specific mutations.
Some of these mutations may therefore represent formative
pathoadaptive mutations that contributed to the initial success
and emergence of the ET12 lineage, whereas others may be
indicative of the ongoing selection pressures in the CF lung.
All of the ET12 strains that we screened contained the same
frameshift mutation in the pyochelin siderophore biosynthesis
gene pchF. Interestingly, the siderophores produced by CF
isolates of B. cenocepacia exhibit strain variation, with SA and
ornibactins being the most prevalent, followed by pyochelin
(32). In a study that investigated pyochelin production in CF
patients from Toronto and Cleveland (125), pyochelin-nega-
tive strains were isolated from patients with moderate or mild
infections, whereas pyochelin-positive strains were more fre-
quently isolated from patients with severe pulmonary disease
going on to suffer high mortality. It is possible that pyochelin
production may play an important role in the progress of B.
cenocepacia disease in CF patients. Switching off expression of
the pyochelin production in ET12 strains may promote persis-
tence in the CF lung and thus the spread of the members of
this lineage between patients.
The long-term maintenance of infection in the CF lung may
result in the streamlining of a pathogen’s virulence and drug
resistance functions, since functions required for the initiation
of acute infections may be selected against during chronic
infections. Evidence for recent pathoadaptive mutations came
from the observation of an independent mutation in a glyco-
syltransferase of an uncharacterized EPS cluster, in K56-2,
another member of the ET12 lineage. Further evidence for
pathoadaptation involving surface carbohydrates came from
the in silico comparison of the B. cenocepacia strains; in the CF
epidemic strain there are mutations in the LPS O-antigen
cluster and an EPS cluster, whereas the related environmental
strain’s clusters remain intact. A reduction in glycosylated sur-
face molecules may provide some advantage, such as reducing
immunorecognition in the lung, thus promoting the mainte-
nance of a long-term infection. In a study of the EPS produc-
tion in a collection of 506 B. cenocepacia strains isolated from
CF patients in the Vancouver area over a 26-year period, more
than half were nonmucoid (151). The study also revealed
evidence of phenotype switching in sequential isolates from
individual patients, with the conversion from mucoid to non-
mucoid being the most prevalent switch. The authors hypoth-
esized that the loss of EPS may reflect adaptation from
persistence in the CF lung to increased disease severity.
Evidence for pathoadaptation can also be found in P. aerugi-
nosa, the major pathogen of the CF lung, where the loss of
acute virulence determinants has been observed in CF isolates,
suggesting that these products are dispensable for long-term
maintenance of P. aeruginosa in vivo (76, 147). A recent study
by Smith et al. investigated genetic adaptation of P. aeruginosa
in CF infections (123). Genomic sequencing of strains isolated
from a CF patient 8 years apart, as well as additional chronic
TABLE 6. Distribution of virulence factor pseudogenes in B. cenocepacia IIIA strainsa
Strain MLST
Distribution of virulence factor pseudogenes for (strain, factor):
BCAL3125§, O antigen BCAL3223§,uncharacterized EPS
BCAL3517†,
T2SS
BCAM0856†,
cepacian capsule
BCAM2228†,
pyochelin
siderophore
J2315* ST28 ISBcen20 interrupted† IS407 interrupted† 110-bp deletion 11-bp deletion Frameshift
BCC0077* ST28 Uninterrupted Uninterrupted In frame 11-bp deletion Frameshift
BCC0179* ST28 Uninterrupted Uninterrupted In frame 11-bp deletion Frameshift
BCC0162* ST28 Uninterrupted Uninterrupted In frame 11-bp deletion Frameshift
BCC0313* ST28 Uninterrupted Uninterrupted In frame 11-bp deletion Frameshift
BCC0016* ST29 As J2315† Uninterrupted In frame 11-bp deletion Frameshift
K56-2* ST30 Uninterrupted ISBcen13
interrupted†
In frame 11-bp deletion Frameshift
BCC1261 ST201 No product Uninterrupted In frame In frame In frame
BCC0222 ST234 No product Uninterrupted In frame In frame In frame
a Multilocus sequence typing (MLST) was used to identify strains related to J2315. The majority of the strains screened belonged to the ET12 lineage (an asterisk
* indicates members of the ET12 lineage). Included in the screening were two non-ET12 strains, BCC1261 (ST201) and BCC0222 (ST234), that are more distantly
related to the strains that belong to ET12 but are members of the same clonal complex as defined by MLST (9) and therefore may be representative of the ancestral
genotype. Where indicated, mutations were determined by sequence data (†) or PCR (§).
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infections, identified that virulence factors genes were the most
prevalent class of genes mutated during the course of infec-
tions. Significantly one of the P. aeruginosa virulence functions
that acquired deleterious mutations was the O antigen (123), a
function also lost in J2315 (101). One additional virulence
mutational adaptation is also shared: mexZ, a negative regu-
lator of the mexXY component of the MexXY-OprM multi-
drug-efflux pump, is orthologous to a J2315 pseudogene
(BCAL1672). In P. aeruginosa, upregulation of this multidrug-
efflux pump is associated with resistance to aminoglycoside
antibiotics that are routinely used to treat infection in CF
patients (124).
Although there are parallels in the potential pathoadapta-
tions of P. aeruginosa and B. cenocepacia, there are also in-
triguing differences. The high frequency of nonmucoid B. ceno-
cepacia isolated from CF patients (151) is in marked contrast
to P. aeruginosa, where isolates from CF patients are more
frequently mucoid than nonmucoid (45). In P. aeruginosa the
production of the EPS alginate is linked to increased morbidity
and mortality (45), whereas strains of B. cenocepacia that are
considered to be more virulent, such as those in the ET12
lineage, have been shown not produce EPS (11, 151). These
somewhat paradoxical observations point toward subtle differ-
ences in the role that the different EPS plays in the mechanism
of pathogenicity and host-cell interaction in these two CF
pathogens.
The genome sequence of J2315 has afforded a tantalizing
glimpse of components of the genome that may promote
growth in the CF lung and provided clues to the potency and
spread of ET12 in recent decades. Evidence from comparative
genomics suggests that loss of functions through mutation and
gain of functions via horizontal gene transfer appear to pro-
mote growth and persistence in the CF lung and contribute to
the success of J2315. Much remains to be learned, however, as
the pathology of B. cenocepacia infections and the physiology
of the CF lung are both complex. The complete genome se-
quence will therefore be a valuable resource for future inves-
tigation into disease caused by B. cenocepacia.
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